Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Irinotecan hydrochloride trihydrate (CPT-11 HCl Trihydrate) keeps DNA from unwinding by inhibiting topoisomerase 1.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
25 mg | 在庫あり | ¥ 8,500 | |||
50 mg | 在庫あり | ¥ 12,000 | |||
100 mg | 在庫あり | ¥ 16,500 | |||
200 mg | 在庫あり | ¥ 22,000 | |||
500 mg | 在庫あり | ¥ 37,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 13,000 |
説明 | Irinotecan hydrochloride trihydrate (CPT-11 HCl Trihydrate) keeps DNA from unwinding by inhibiting topoisomerase 1. |
In vitro | In the liver, stomach, duodenum, and colon, a single dose of Irinotecan significantly increases the covalent binding of topoisomerase I to DNA. Compared to the control group, there is a marked increase in DNA strand breaks within the colonic mucosal cells in the Irinotecan-treated group. In COLO320 xenografts, Irinotecan induces a 92% maximum growth inhibition. |
In vivo | In LoVo and HT-29 cell lines, Irinotecan induces a similar number of cleavable complexes at IC50 concentrations, with no significant difference observed between the two. The formation of cleavable complexes by SN-38 is concentration-dependent and consistent across both cell lines. Notably, intracellular accumulation of Irinotecan differs significantly, with consistently higher levels in HT-29 cells compared to LoVo cells. Carboxylesterase activation of Irinotecan to SN-38 (primarily in the liver) facilitates interaction with its target, topoisomerase I, in plasma, intestines, and tumor tissues. The hydrolysis of Irinotecan’s lactone E-ring and SN-38 is reversible in aqueous solution, with the interconversion of their carboxylate and lactone forms dependent on temperature and pH. For the same concentration of SN-38 glucuronide and Irinotecan in tumor and normal tissues, the yield of SN-38 via β-glucuronidase mediation exceeds that of SN-38 produced from Irinotecan. In SCLC cell lines, Irinotecan exhibits markedly greater activity than in NSCLC cell lines, while tissue histology does not reveal significant differences in SN-38 efficacy. |
細胞研究 | Exponentially growing cells (LoVo and HT-29 cells) are seeded in 20 cm2 Petri dishes with an optimal cell number for each cell line (2 × 104 for LoVo cells, 105 for HT-29 cells). They are treated 2 days later with increasing concentrations of Irinotecan or SN-38 for one cell doubling time (24 hours for LoVo cells, 40 hours for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the Irinotecan or SN-38 concentrations responsible for 50% growth inhibition as compared with cells incubated without Irinotecan or SN-38. (Only for Reference) |
植物由来 |
別名 | Irinotecan HCl Trihydrate, CPT-11 HCl Trihydrate |
分子量 | 677.18 |
分子式 | C33H45ClN4O9 |
CAS No. | 136572-09-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 1 mg/mL (1.47 mM)
Ethanol: 7 mg/mL (10.33 mM)
DMSO: 45 mg/mL (66.45 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Irinotecan hydrochloride trihydrate 136572-09-3 Autophagy DNA Damage/DNA Repair Topoisomerase Irinotecan HCl Trihydrate CPT-11 hydrochloride inhibit Irinotecan hydrochloride Inhibitor (+)-Irinotecan hydrochloride Irinotecan hydrochloride Trihydrate Irinotecan HCl CPT-11 HCl Trihydrate Irinotecan Hydrochloride CPT-11 HCl inhibitor